Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.130% | -1.692% | -17.540% | -27.044% | -19.560% | -31.116% | -35.716% |
| Opko Health Inc. | 4.910% | 0.639% | -6.512% | -35.920% | -10.457% | 3.258% | -73.926% |
| Amicus Therapeutics Inc. | 0.000% | -0.826% | 0.840% | 39.535% | 0.000% | -0.892% | 24.352% |
Comments
News
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.
According to
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade.
According to a SEC